Melbourne, Australia and Minneapolis, Minn., Aug. 14, 2017 /PRNewswire/ -- Global Kinetics Corporation (GKC), a digital health company revolutionizing the management of Parkinson's disease, announced today it has recently received Notice of Allowance for U.S. patent application 12/997540, protecting the company's lead product, the Personal KinetiGraph™ (PKG™) (Parkinson's Kinetigraph™ outside of the U.S.) system, which the company is marketing in the U.S. The patent application pertains to the objective measurement of bradykinesia. Bradykinesia, or slowness of movement, is one of the most common symptoms, and a defining feature, of Parkinson's disease. The capacity to continuously measure this movement symptom underpins the PKG system.

"The allowance of this application supports GKC's continued progress in the commercialization of our novel, U.S. FDA-cleared PKG system, which is being used to support the management of Parkinson's disease in over 215 clinics in 16 countries around the world," said GKC's global head of business development and legal affairs, Michelle Goldsmith. "We are aggressively pursuing clinical and commercial milestones that will ultimately enable us to make measurable change in the lives of people with Parkinson's."

The PKG system, developed by Professor Malcolm Horne and Dr. Rob Griffiths following many years of research at Melbourne's Howard Florey Institute and Monash University, incorporates a patient-friendly wrist-worn device to record body movements over several days as people go about their daily lives. The PKG system is the only commercially available mobile health technology which provides clinically meaningful measurement of the key symptoms of Parkinson's using cloud-based proprietary algorithms that measure bradykinesia, dyskinesia, tremor, and the relationships of these to medication timing, sleep and exercise.
Inaccurate assessment of Parkinson's symptoms may result in patients experiencing uncontrolled symptoms, reducing their quality of life and increasing healthcare costs. By adding the PKG system into a patient's routine care, treating clinicians now have an effective tool that assists them to augment their clinical assessment with GKC's proprietary objective data, captured by the PKG watch over seven days.

"GKC has long held the view that measurement is key to optimal management in Parkinson's. Our algorithms underpin GKC's ability to provide clinically meaningful and actionable information about Parkinson's symptoms to clinicians," explained Professor Horne, GKC's co-founder and chief scientific officer.

Alzheimers/Neurology Homepage